Trump drug pricing order may be weeks away - (CNBC via NewsPoints Desk)

  • Sources revealed than US President Donald Trump's expected executive order focused on drug pricing may not be ready for a few weeks, CNBC reported Tuesday.

  • People familiar with the matter noted that the current proposals do not seek major changes such as allowing Medicare to negotiate drug prices, focusing instead on policies such as value-based pricing.

  • "[There is a] general recognition that the Trump threat to regulate drug prices in a harmful way is receding," Leerink analyst Geoff Porges commented, adding "the light at the end of the tunnel is now in the tunnel!"

  • Meanwhile, FDA Commissioner Scott Gottlieb has called for the agency to attempt to increase drug affordability by increasing competition.

  • The agency has also signalled willingness to approve treatmetns based on genetic signatures instead of for specific conditions, as indicated by the recent approval of Merck & Co.'s Keytruda for microsatellite instability-high or mismatch repair deficient cancers.

  • "Gottlieb endorsing genetically defined drug approvals...particularly in oncology is very positive," Porges explained, noting that such a move would benefit drugmakers such as Epizyme, Loxo Oncology, Merck and Vertex Pharmaceuticals.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.